Perforomist (formoterol fumarate) product packaging


Help Them Manage Their COPD

Twice-daily maintenance treatment with nebulized PERFOROMIST® (formoterol fumarate) can help patients manage their COPD.1,3 In a 12 week clinical trial in moderate to severe COPD patients (n=351), PERFOROMIST showed an effect on FEV1 improvement for up to 12 hours.1,3†

PERFOROMIST is a long-acting beta2-adrenergic agonist (LABA) that:

  • Provides rapid onset of bronchodilation that lasts up to 12 hours1,3†
    •  Works in as soon as 5 minutes.3 The median time to onset of bronchodilation was 11.7 minutes, defined as a 15% increase in FEV11,3†
    •  78% of patients achieved a 15% increase from baseline FEV1 following the first dose of PERFOROMIST Inhalation Solution.1,3†

    •  PERFOROMIST Inhalation Solution is not indicated for relief of acute symptoms, and extra doses should not be used for that purpose.1
  • Reduces need for rescue therapy1,3‡

    •  In a pivotal trial, nebulized PERFOROMIST reduced rescue inhaler use by up to 42% (-1.25 puffs a day). Patients treated with PERFOROMIST Inhalation Solution used less rescue albuterol compared to patients treated with placebo during the course of a 12-week study.1,3
  • Relaxes the muscles around the airways in the lungs to help manage COPD bronchoconstriction.1
  • Doesn’t require hand-breath coordination; breathing as calmly, deeply and evenly as possible is sufficient for proper dosing.1
  • Maintained bronchodilation as indicated by sustained FEV1 AUC up to 12 weeks1,3‡
    •  Tolerance to the effects of inhaled beta-agonists may occur with regularly scheduled, chronic use.1      
prescription script example
  • Delivers rapid and maintained bronchodilation1,3‡
    •  PERFOROMIST Inhalation Solution is not indicated for relief of acute symptoms, and extra doses should not be used for that purpose.1
  • Reduced albuterol use
    •  1.25 fewer puffs/day for patients1,3‡
  • Can be used in any standard jet nebulizer1
  • PERFOROMIST can be stored in room temperature for up to 3 months1
    •  Longer than any other nebulized LABA

    Covered for up to 100% of patients with
    Medicare Part B*

prescription script example
* Site of care will determine coverage. This is not a guarantee of coverage. Check with patient’s insurance provider for coverage rules and restrictions.
† Other codes may apply.

A randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group study in 351 moderate-to-severe COPD patients evaluating the efficacy and safety of PERFOROMIST (20 mcg/2 mL twice daily) over 12 weeks. PERFOROMIST group (n=123); placebo group (n=114). Sustained improvement was measured by serial FEV1 for 12 hours postdose, the primary efficacy analysis compared with placebo when evaluated at the 12 week endpoint. Also evaluated use of rescue albuterol during the trial.1,3